195615-83-9

Blarcamesine (10 mg/kg, 30 mg/kg; p.o.; daily; for 6.5 weeks) ameliorates motor deficits in Mecp2 HET mice with chronic administration^[1].
Blarcamesine ameliorates acoustic startle deficit in Mecp2 HET mice^[1].
Blarcamesine reverses deficits in visual acuity in older Mecp2 HET mice using the optokinetic response^[1].
Blarcamesine produces minimal effects on body weight gain in Mecp2 HET mice^[1].